The potential application of MAO‐B inhibitors in the treatment of neurodegenerative diseases has drawn more attention, not just for their roles in the metabolism of monoamine neurotransmitters and in mitigating oxidative stress but also for their additional neuroprotective and neurorescue properties, which are advantageous for AD treatment. Here, MAOB is linked to Alzheimer disease.